Endocrine Abstracts

Introduction: Everolimus is a drug selective inhibitor of mTOR and approved by the FDA in 2011 for treatment of neuroendocrine tumors of pancreatic origin unresectable. Our objective was to evaluate the efficacy and safety of everolimus in a patient with malignant pancreatic head insulinoma.Case: This is a 31 year old man who complains of epigastric pain, dizziness, sweating and syncope related to exercise. During admission is objectively severe hypoglyc...